valneva - Search News

News

Valneva SE, chikungunya and FDA

Valneva shares tumble after suspension of US chikungunya vaccine licence

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the licence for its chikungunya vaccine, Ixchiq, with immediate effect, citing serious safety concerns.

BioSpace · 2d

FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’

· 2d

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

MedCity News1d

FDA Suspends Valneva Vaccine’s License Following New Reports of Adverse Events

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

Jefferies lowers Valneva stock price target to $14 on FDA suspension

Investing.com - Jefferies has reduced its price target on Valneva SE (NASDAQ:VALN) to $14.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $9.13, Valneva has shown ...

Asianet Newsable on MSN1d

Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact

A nalysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...

TipRanks on MSN4d

Valneva SE (ADR) trading halted, news pending

SE (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results